About Macrodeep
New report 2026 AI SDR market benchmark: six platforms, eight workflow stages See the results →

Raportul

Știri verificate despre finanțări, sedii centrale și leadership de la cele mai inovatoare companii din lume

84 rapoarte și mai multe

Actualizat zilnic cu ultimele informații de piață
Fundraising
KymaThera

KymaThera Raises $80M Series B for Selective PI3Kα Inhibitor

KymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3Kα inhibitor for cancer and vascular malformations.

SalesTools Research
Oct 6, 2026
2 min read•$80M
Leadership
NeoGenomics

NeoGenomics Names Warren Stone Chief Executive Officer

NeoGenomics named President and COO Warren Stone CEO effective January 4, 2027, with Tony Zook becoming Executive Chair and the company emphasizing strategic continuity.

SalesTools Research
Oct 5, 2026
2 min read
Fundraising
Teal Health

Teal Health Raises $22M Series A for At-Home HPV Cervical Cancer Screening

Teal Health raised a $22 million Series A led by .406 Ventures to expand partnerships and access to its at-home HPV cervical cancer screening.

SalesTools Research
Sep 22, 2026
2 min read•$22M
Fundraising
Altis Labs

Altis Labs Raises $25M Series A for AI Clinical-Trial Endpoints

Altis Labs raised a $25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to expand AI endpoints for oncology clinical trials.

SalesTools Research
Sep 17, 2026
2 min read•$25M
Fundraising
Solstice Oncology

Solstice Oncology Raises $225M Series A for Neoadjuvant Immuno-Oncology

Solstice Oncology launched with a $225 million Series A led by RA Capital Management to advance porustobart, a neoadjuvant immuno-oncology therapy.

SalesTools Research
Sep 9, 2026
2 min read•$225M
Fundraising
Cloverleaf Bio

Cloverleaf Bio Raises $33M Seed Round for RNA Cancer Therapeutics

Cloverleaf Bio closed an oversubscribed $33 million seed round to advance engineered tRNA therapeutics for liver and colorectal cancers.

SalesTools Research
Sep 8, 2026
2 min read•$33M
Fundraising
Craif

Craif Closes Approximately $33M Series D for Urine-Based Cancer Test

Craif closed an approximately $33 million Series D, made up of about $30.7 million in equity and about $3.3 million in debt and co-led by Granite-Integral and Tauns Co., Ltd., bringing total capital raised to roughly $88 million.

SalesTools Research
Aug 18, 2026
2 min read•$33M
Fundraising
CORE Biomedicine

CORE Biomedicine Raises $21M Series A for Precision Oncology Therapeutics

CORE Biomedicine closed a $21 million Series A co-led by UTokyo Innovation Platform and Elikon Venture, and its Japanese subsidiary received an AMED grant.

SalesTools Research
Jul 28, 2026
2 min read•$21M
Fundraising
AdvanCell

AdvanCell Raises $315M Series D for Targeted Alpha Therapies

AdvanCell closed an oversubscribed, upsized $315 million Series D led by Ally Bridge Group and co-led by Alpha Wave to advance ADVC001 toward Phase 3 and expand U.S. manufacturing.

SalesTools Research
Jul 15, 2026
2 min read•$315M
Pagina 1

Afișare 9 rapoarte • Pagina 1 • Categorie: all

Rămâneți înaintea pieței

Primiți perspective săptămânale în inbox. Fără spam, doar inteligență.